This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why you Should Retain Veeva Systems Stock in Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
Buy These 5 Stocks Set to Win Big After Earnings Results This Week
by Nalak Das
We have narrowed our search to five corporate behemoths set to report earnings results this week. These are: CAH, LOGI, NOW, GLW, ADP.
Cardinal Health to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Despite recent supply-chain challenges, new facilities and growth in branded and specialty pharmaceutical sales are likely to have driven CAH's performance in the fiscal second quarter.
VEEV Stock Falls Despite Tie-Up to Streamline Customers' Operations
by Zacks Equity Research
Veeva Systems aims to simplify master data configuration during LIMS implementation and site deployment and enable companies to advance beyond legacy QC systems.
Cardinal Health (CAH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market
by Zacks Equity Research
ABT delivers a strong underlying base business performance for the fourth quarter of 2024.
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and AIM ImmunoTech Inc. (AIM) have performed compared to their sector so far this year.
Prestige Consumer Stock Up 29.9% in a Year: What's Behind the Surge?
by Zacks Equity Research
PBH sees remarkable gains from long-term brand-building strategies and developing the e-commerce channel.
Cardinal Health (CAH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed the most recent trading day at $127.83, moving +1.24% from the previous trading session.
Globus Medical Surges 62.1% in a Year: What's Driving the Stock?
by Zacks Equity Research
GMED's strong synergies from the NuVasive merger and robust performance in the musculoskeletal solutions space bode well for investors.
MCK Stock Gains 4% in 3 Weeks: Should You Buy, Hold or Sell?
by Indrajit Bandyopadhyay
McKesson's strategic growth in oncology, biopharma and tech drives momentum in 2025. Will MCK overcome its sustaining challenges with robust finances and innovation?
Masimo Stock Gains Following Solid Preliminary Q4 Revenues
by Zacks Equity Research
MASI's revenue growth in the fourth quarter is likely to have been boosted by the continued robust adoption of its products.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cardinal Health Stock May Gain With New Texas Distribution Center
by Zacks Equity Research
CAH announces the ongoing construction of a new distribution center in Texas, which is likely to support its at-Home Solutions business.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Cardinal Health (CAH) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Cardinal Health (CAH) closed at $124.71, marking a +0.55% move from the previous day.
Inogen Stock Gains Following Solid Preliminary Q4 Revenues
by Zacks Equity Research
INGN's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
Merit Medical Stock Gains Following Solid Preliminary Q4 Revenues
by Zacks Equity Research
MMSI's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
NEOG Prelim Q2 Earnings Meet, '25 Sales View Down, Stock Falls
by Zacks Equity Research
NEOG's Food Safety business witnesses a slight year-over-year decrease in revenues for the second quarter of fiscal 2025.
The Zacks Analyst Blog Highlights Ensign, Cardinal Health, Atmos Energy and IDACORP
by Zacks Equity Research
Ensign, Cardinal Health, Atmos Energy and IDACORP are included in this Analyst Blog.
Consumer Sentiment Declines Amid Rate Cut Uncertainty: 4 Safe Bets
by Ritujay Ghosh
Low-beta defensive stocks like ENSG, CAH, ATO and IDA are a safe bet during times of market volatility.
Inspire Medical Stock Falls Despite Solid Preliminary Q4 Revenues
by Zacks Equity Research
INSP's revenue growth in the fourth quarter is likely to have been boosted by increased market penetration in existing centers and expansion into new implanting centers.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.